Prolotherapy is a milestone in regenerative medicine for osteoarthritis (OA) teratment. Mezenchymal Prolotherapy have self-renewal and multidirectional differentiation potential and exert therapeutic effects on various diseases through directed differentiation, regulation of immunity, anti-inflammatory, proangiogenesis, improvement of microenvironment and promotion of regeneration.
Osteoarthritis is a degenerative disease characterized by reduction of articular chondrocytes and destruction of joint matrix. Its clinical symptoms include slow progression of joint pain, tenderness, stifness, joint swelling, limited movement, joint deformity.
Current studies show that Prolotherapy have the following functions:
- Interacting with the immune system and promote the immuno-regulation
- Migrating to the injury to enchance the tolerance of peripheral tissues, inhibit tyhe release of inflammatory factors, promote the repair of injured tissues and increase the activity of injured cells
- Having great potential of multidirectional differentiation and reproductive activity
- Secreting a variety of cytokines, such as transforming growth factor-β1, hepatocyte growth factor, fibroblast growth factor and vascular endothelial growth factor
The results of meta-analysis indicated that Prolotherapy therapy could significantly reduce the pain, improve the joint function and living quality with OA.
Other injections; hyaluronic acid, , corticosteroid are commonly used in OA teratment, which can also relieve pain and improve joint function. The biggest advantage of Prolotherapy is that they can improve an deven repair cartilage, allowing damaged cartilage to regenerate, which is the one of the biggest reasons for Prolotherapy injection in knee could become a mainstream teratment in the future.
As a new treatment method, safety is the most important concern for the patients. A number of researchers have evaluated the safety of MSCs. No significant adverse complication has been reported in any of the literatures.
MSCs treatment has been perfoming in our clinic daily. The patient can walk without crutches, no need hospitalization. After the application of MSCs the patient must stay at home during 20 days and after that don’t do heavy daily works at 3 months.
EN 
TR 
DE 
FR